Literature DB >> 21173098

A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis.

Domenico Girelli1, Paola Trombini, Fabiana Busti, Natascia Campostrini, Marco Sandri, Sara Pelucchi, Mark Westerman, Tomas Ganz, Elizabeta Nemeth, Alberto Piperno, Clara Camaschella.   

Abstract

BACKGROUND: Inadequate hepcidin production leads to iron overload in nearly all types of hemochromatosis. We explored the acute response of hepcidin to iron challenge in 25 patients with HFE-hemochromatosis, in two with TFR2-hemochromatosis and in 13 controls. Sixteen patients (10 C282Y/C282Y homozygotes, 6 C282Y/H63D compound heterozygotes) had increased iron stores, while nine (6 C282Y/C282Y homozygotes, 3 C282Y/H63D compound heterozygotes) were studied after phlebotomy-induced normalization of iron stores. DESIGN AND METHODS: We analyzed serum iron, transferrin saturation, and serum hepcidin by both enzyme-linked immunosorbent assay and mass-spectrometry at baseline, and 4, 8, 12 and 24 hours after a single 65-mg dose of oral iron.
RESULTS: Serum iron and transferrin saturation significantly increased at 4 hours and returned to baseline values at 8-12 hours in all groups, except in the iron-normalized patients who showed the highest and longest increase of both parameters. The level of hepcidin increased significantly at 4 hours and returned to baseline at 24 hours in controls and in the C282Y/H63D compound heterozygotes at diagnosis. The hepcidin response was smaller in C282Y-homozygotes than in controls, barely detectable in the patients with iron-depleted HFE-hemochromatosis and absent in those with TFR2-hemochromatosis. Conclusions Our results are consistent with a scenario in which TFR2 plays a prominent and HFE a contributory role in the hepcidin response to a dose of oral iron. In iron-normalized patients with HFE hemochromatosis, both the low baseline hepcidin level and the weak response to iron contribute to hyperabsorption of iron.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173098      PMCID: PMC3069225          DOI: 10.3324/haematol.2010.033449

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  35 in total

1.  (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies.

Authors:  Joyce J C Kroot; Jan C M Hendriks; Coby M M Laarakkers; Siem M Klaver; Erwin H J M Kemna; Harold Tjalsma; Dorine W Swinkels
Journal:  Anal Biochem       Date:  2009-03-31       Impact factor: 3.365

2.  Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization.

Authors:  Joyce J C Kroot; Erwin H J M Kemna; Sukhvinder S Bansal; Mark Busbridge; Natascia Campostrini; Domenico Girelli; Robert C Hider; Vasiliki Koliaraki; Avgi Mamalaki; Gordana Olbina; Naohisa Tomosugi; Chris Tselepis; Douglas G Ward; Tomas Ganz; Jan C M Hendriks; Dorine W Swinkels
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

3.  Diferric transferrin regulates transferrin receptor 2 protein stability.

Authors:  Martha B Johnson; Caroline A Enns
Journal:  Blood       Date:  2004-08-19       Impact factor: 22.113

4.  Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis.

Authors:  Hiroshi Kawabata; Robert E Fleming; Dorina Gui; Seo Y Moon; Takayuki Saitoh; James O'Kelly; Yutaka Umehara; Yuji Wano; Jonathan W Said; H Phillip Koeffler
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

Review 5.  Hepcidin assay in serum by SELDI-TOF-MS and other approaches.

Authors:  Annalisa Castagna; Natascia Campostrini; Federica Zaninotto; Domenico Girelli
Journal:  J Proteomics       Date:  2009-08-13       Impact factor: 4.044

6.  Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload.

Authors:  Alberto Piperno; Antonella Roetto; Raffaella Mariani; Sara Pelucchi; Chiara Corengia; Filomena Daraio; Antonio Piga; Giovanni Garozzo; Clara Camaschella
Journal:  Haematologica       Date:  2004-03       Impact factor: 9.941

7.  Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression.

Authors:  Junwei Gao; Juxing Chen; Maxwell Kramer; Hidekazu Tsukamoto; An-Sheng Zhang; Caroline A Enns
Journal:  Cell Metab       Date:  2009-03       Impact factor: 27.287

8.  Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.

Authors:  George Papanikolaou; Mark E Samuels; Erwin H Ludwig; Marcia L E MacDonald; Patrick L Franchini; Marie-Pierre Dubé; Lisa Andres; Julie MacFarlane; Nikos Sakellaropoulos; Marianna Politou; Elizabeta Nemeth; Jay Thompson; Jenni K Risler; Catherine Zaborowska; Ryan Babakaiff; Christopher C Radomski; Terry D Pape; Owen Davidas; John Christakis; Pierre Brissot; Gillian Lockitch; Tomas Ganz; Michael R Hayden; Y Paul Goldberg
Journal:  Nat Genet       Date:  2003-11-30       Impact factor: 38.330

9.  Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene.

Authors:  Domenico Girelli; Claudia Bozzini; Antonella Roetto; Federica Alberti; Filomena Daraio; Romano Colombari; Oliviero Olivieri; Roberto Corrocher; Clara Camaschella
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

10.  Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry.

Authors:  Dorine W Swinkels; Domenico Girelli; Coby Laarakkers; Joyce Kroot; Natascia Campostrini; Erwin H J M Kemna; Harold Tjalsma
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

View more
  29 in total

Review 1.  Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2018-05-31       Impact factor: 11.848

2.  Novel observations in hereditary hemochromatosis: potential implications for clinical strategies.

Authors:  Dorine W Swinkels; Robert E Fleming
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

3.  Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing.

Authors:  Ludovica Ferbo; Paola M Manzini; Sadaf Badar; Natascia Campostrini; Alberto Ferrarini; Massimo Delledonne; Tiziana Francisci; Valter Tassi; Adriano Valfrè; Anna M Dall'omo; Sergio D'antico; Domenico Girelli; Antonella Roetto; Marco De Gobbi
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

4.  Inflammation-induced hepcidin is associated with the development of anemia and coronary artery lesions in Kawasaki disease.

Authors:  Ho-Chang Kuo; Ya-Ling Yang; Jiin-Haur Chuang; Mao-Meng Tiao; Hong-Ren Yu; Li-Tung Huang; Kuender D Yang; Wei-Chiao Chang; Chiu-Ping Lee; Ying-Hsien Huang
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

Review 5.  Hereditary hemochromatosis and transferrin receptor 2.

Authors:  Juxing Chen; Caroline A Enns
Journal:  Biochim Biophys Acta       Date:  2011-08-16

Review 6.  Mechanisms of mammalian iron homeostasis.

Authors:  Kostas Pantopoulos; Suheel Kumar Porwal; Alan Tartakoff; L Devireddy
Journal:  Biochemistry       Date:  2012-07-09       Impact factor: 3.162

7.  Estimates of total body iron indicate 19 mg and 38 mg oral iron are equivalent for the mitigation of iron deficiency in individuals experiencing repeated phlebotomy.

Authors:  Walter Bialkowski; Joseph E Kiss; David J Wright; Ritchard Cable; Rebecca Birch; Pam D'Andrea; Barbara J Bryant; Bryan R Spencer; Alan E Mast
Journal:  Am J Hematol       Date:  2017-06-09       Impact factor: 10.047

8.  Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors.

Authors:  Sant-Rayn Pasricha; Zoe McQuilten; Mark Westerman; Anthony Keller; Elizabeta Nemeth; Tomas Ganz; Erica Wood
Journal:  Haematologica       Date:  2011-04-20       Impact factor: 9.941

9.  Clinical Immunoassay for Human Hepcidin Predicts Iron Deficiency in First-Time Blood Donors.

Authors:  Patrick Gutschow; Huiling Han; Gordana Olbina; Keith Westerman; Elizabeta Nemeth; Tomas Ganz; Karen Copeland; Mark Westerman; Vaughn Ostland
Journal:  J Appl Lab Med       Date:  2020-09-01

Review 10.  Hepcidin in the diagnosis of iron disorders.

Authors:  Domenico Girelli; Elizabeta Nemeth; Dorine W Swinkels
Journal:  Blood       Date:  2016-04-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.